88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com
Settore/i:
Settore:
Impiegati a tempo pieno: 383
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Brian M. Goff M.B.A. | CEO & Director | 1,23M | N/D | 1969 |
Ms. Cecilia Jones | Chief Financial Officer | 403,36k | N/D | 1975 |
Mr. James William Burns | Corporate Secretary & Chief Legal Officer | 660,33k | N/D | 1978 |
Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 769,2k | N/D | 1981 |
Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | 50k | N/D | 1949 |
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | 1946 |
Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | N/D | N/D | 1953 |
Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | 1956 |
Mr. T. J. Washburn Jr. | Principal Accounting Officer | N/D | N/D | 1981 |
Dr. Clive Patience Ph.D. | Chief Technical Operations Officer | N/D | N/D | 1964 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
L'ISS Governance QualityScore di Agios Pharmaceuticals, Inc. al 1 marzo 2024 è 5. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 7; retribuzione: 6.